About us Contacts Drug interactions: 390 212
Drug search by name

Fostamatinib disodium and Kaletra Oral Solution

Determining the interaction of Fostamatinib disodium and Kaletra Oral Solution and the possibility of their joint administration.

Check result:
Fostamatinib disodium <> Kaletra Oral Solution
Relevance: 23.05.2022 Reviewer: Shkutko P.M., M.D., in

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

Consumer:

Ritonavir may significantly increase the blood levels of fostamatinib. This may increase the risk and/or severity of side effects such as nausea, diarrhea, high blood pressure, liver problems, and low white blood cell counts. You may also be more likely to develop infections as a result of low white blood cell counts. You should seek immediate medical attention if you have signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination. Talk to your doctor if you have any questions or concerns. Your doctor may be able to prescribe alternatives that do not interact, or you may need a dose adjustment or more frequent monitoring to safely use both medications. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Professional:

MONITOR CLOSELY: Coadministration of fostamatinib with potent inhibitors of CYP450 3A4 may significantly increase exposure to the active metabolite known as R406, the predominant moiety in the systemic circulation following fostamatinib administration. Fostamatinib is metabolized in the gut by alkaline phosphatase to R406, which then undergoes oxidation via CYP450 3A4 and glucuronidation via UGT1A9. When a single 80 mg dose of fostamatinib (0.53 times the 150 mg dosage) was administered with the potent CYP450 3A4 inhibitor ketoconazole (200 mg twice daily for 3.5 days), R406 peak plasma concentration (Cmax) and systemic exposure (AUC) increased on average by 37% and 102%, respectively, compared to fostamatinib administered alone. Increased exposure to R406 may result in increased risk of adverse effects such as diarrhea, hepatotoxicity, hypertension, and neutropenia.

MANAGEMENT: Patients should be monitored for toxicities of fostamatinib during concomitant use of potent CYP450 3A4 inhibitors, and the fostamatinib dosage adjusted as necessary in accordance with the product labeling.

References
  • "Product Information. Tavalisse (fostamatinib)." Rigel Pharmaceuticals, South San Francisco, CA.
Fostamatinib disodium

Generic Name: fostamatinib

Brand name: Tavalisse

Synonyms: Fostamatinib disodium (Oral)

Kaletra Oral Solution

Generic Name: lopinavir / ritonavir

Brand name: Kaletra

Synonyms: Kaletra

In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.

Interaction with food and lifestyle